Human Investing’s Moderna MRNA Stock Holding History

Human Investing’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,710	Closed	-$1.04M	–	103
2021 Q3	$1.04M	Buy	+2,710	New	+$999K	0.25%	71
2020 Q3	–	Sell	-200	Closed	-$13K	–	326
2020 Q2	$13K	Buy	+200	New	+$11K	﹤0.01%	211

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Human Investing's MRNA Position: Q4 2021 in Review

Human Investing sold out of Moderna (MRNA) in Q4 2021, closing a stake of 2,710 shares — an estimated $1.04M sold.

Human Investing first reported a position in MRNA in Q2 2020 and held it in 2 quarters. The position peaked at $1.04M in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Human Investing reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Human Investing sold 2,710 Moderna shares in Q4 2021, an estimated $1.04M.
Human Investing first reported a position in Moderna in Q2 2020 and held it in 2 quarters.
Human Investing's Moderna position peaked at $1.04M in Q3 2021.
1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Human Investing's 13F filing for Q4 2021, filed 10 Feb 2022.